CEO of Apogee Therapeutics Executes $1.2 Million Insider Sell‑off While Maintaining 18% Stake in Company Shares

Insider Selling Swells at Apogee Therapeutics

On June 10, 2026 the CEO of Apogee Therapeutics, Michael Thomas Henderson, executed a Rule 10b‑5‑1 trading plan that saw him liquidate 6 770 shares at $82.21, 7 654 shares at $82.78, 1 080 shares at $84.18, 1 577 shares at $85.19, 2 305 shares at $86.27 and 614 shares at $86.89. The total proceeds of roughly $1.2 million came from a series of “sell” transactions that were part of a pre‑planned plan adopted last August. The plan’s price range—$81.57 to $87.16—was carefully designed to smooth out market impact, and the SEC has been asked to verify the exact splits if needed.

What Does This Mean for Investors? The timing is noteworthy. The company’s stock closed at $89.50 on the same day, and its weekly change is up 1.6 %, while the market cap sits at $6.24 billion. The CEO’s selling activity, however, does not signal an abrupt loss of confidence; it is consistent with the company’s broader insider‑trading pattern. Since January 2026, Mr. Henderson has sold an aggregate of over 70 000 shares, a volume that matches or exceeds the average daily volume of the stock. Yet he continues to hold roughly 1.1 million shares—about 18 % of the outstanding equity—underscoring a long‑term stake that remains strong even as he takes advantage of a 107 % year‑to‑date gain.

Insider Activity Across the Board The same day the CEO sold, the board’s other directors—Kiselak, Shah, McKenna, Jones, Fox and Bollinger—granted themselves options covering 7 657 shares each, vesting a year after the grant. These options, due to expire in 2036, are standard incentive instruments and do not reflect any immediate ownership change. Meanwhile, other executives such as Chief Medical Officer Carl Dambkowski and CFO Jane Henderson have been buying and selling in amounts that are modest relative to the company’s trading volume, indicating a balanced approach to personal portfolio management.

Profile of CEO Michael H. Thomas Historically, Mr. Henderson’s trades have been largely “sell” transactions, with the largest single block occurring in late May 2026 (18 659 shares). He typically sells in batches of 1–10 000 shares, often at the lower end of the trading range, and rarely sells more than 10 000 shares in a single day. His pattern suggests a disciplined use of a Rule 10b‑5‑1 plan rather than opportunistic trading. Importantly, the plan was adopted in August 2025, a time when the company was announcing a new antibody platform that has already driven a 5 % month‑over‑month gain. This timing indicates the plan was set up to capture upside while limiting market distortion.

Investor Takeaway For the market, the CEO’s selling volume is a reminder that insiders routinely liquidate shares to diversify wealth or rebalance portfolios. The 48‑point positive social‑media sentiment and a 90 % buzz index indicate that the broader community remains upbeat, with no significant negative narrative emerging from the transaction. Apogee’s fundamentals—high‑growth therapeutic pipeline, robust revenue growth and a solid valuation—still outweigh the short‑term sell pressure. Investors should view the CEO’s trades as part of a pre‑planned strategy rather than a bearish signal, and focus on the company’s long‑term product development milestones and regulatory approvals in the coming quarters.